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ABSTRACT

CHEMOPREVENTIVE EFFECTS OF CRANBERRY IN ASSOCIATION WITH THE
ALTERATION OF GUT MICROBIOTA
SEPTEMTER 2016
XIAOKUN CAI,
B.S., SOUTH CHINA AGRICULTURAL UNIVERSITY, GUANGZHOU, CHINA
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA
Directed by: Professor Hang Xiao
Accumulating evidence showed that microbiota play important roles in colonic
inflammation and inflammation-associated colon carcinogenesis. Fruits and vegetable are known
to have protective effects against colon carcinogenesis. Cranberry fruit contains large amount of
flavonoids, phenolic acids and dietary fiber, which has been studied for their potential
chemopreventive effect from in vitro model. To better understand the effect, we studied the
protective effects of whole cranberry powder against colitis in mice treated with dextran sulfate
sodium (DSS) and inflammation-associated colon carcinogenesis in mic treated with
azoxymethane (AOM) and DSS, and its impact on gut microbiota.
In DSS-induced colitis mice model, 1.5% (w/w) whole cranberry powder mixed with
regular diet was provided to mice for 32 days. The oral administration of cranberry powder
significantly reduced the DAI score and inhibited the inflammation in the colon compared to the
control group. Moreover, cranberry diet increase the richness and evenness of gut microbiota in
mice, which played an important role on inflammation prevention. Oral intake of cranberry can
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significantly inhibited the growth of Akkermansia and Sutterella while protect the growth of
Bifidobacterium and Lactobacillus.
In AOM-induced colonic cancer mice model, whole cranberry powder was administered
to mice through diet at 1.5% w/w for 20 weeks. Our results demonstrated that treatment with
cranberry powder significantly reduced the incidence and multiplicity of colon tumors. These
protective effects were associated with decreased inflammation and increased apoptosis in the
colonic tumors. Using 16s rRNA amplicon sequencing, we analyzed the structure and predicted
the function of fecal microbiota of the mice. Compared to that of the negative control group,
fecal microbiota of AOM/DSS-treated mice showed relative abundance shifts, a decrease of the
abundance of Akkmansia. Dietary treatment with whole cranberry powder reversed
aforementioned alterations in the fecal microbiota of AOM/DSS-treated mice. Moreover, whole
cranberry powder also increased the number of Bifidobacterium and Lactobacillus in the fecal
microbiota. These composition alterations induced by whole cranberry powder were associated
with suppressed colonic inflammation and carcinogenesis.
In conclusion, our results demonstrated that whole cranberry powder modulated the
composition of gut microbiota in both DSS-treated and AOM/DSS-treated mice, which may
contribute to its anti-inflammatory and anti-carcinogenic effects in the colon.
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CHAPTER 1
INTRODUCTION
Due to the aging and the increasing population around the word, cancer burden increase
dramatically. The growing adoption of cancer causing behaviors, including smoking and western
diet, accelerate the growth rate of cancer incidence[1]. Colorectal cancer is one of the most
commonly diagnosed cancer around the world, which caused about 608,700 deaths in 2008.
North America is one of the highest colorectal cancer incidence area which can be attributed to
western diet, obesity, alcohol consumption and physical inactivity [2]. Western diet, which
contains excessive animal fat and red meat, and little dietary fiber and vegetables, contribute up
to 80% of CRC incidence [3].
In the last decade, ample animal and epidemiological studies have revealed the role of
inflammation on all steps of colon tumorigenesis. Inflammatory bowel disease(IBD), including
Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammation of all or part of
digestive tract, which is a serious risk factor for one subtype of CRC, colitis-associated cancer
(CAC). Comparing with other types of CRC, CAC has higher mortality since it is difficult to
treat basing on current therapy method [4].
Gut microbiota is a complex communities of microorganisms which inhabiting in the
gastrointestinal tract. the human gut microbiota contains approximately 500~1000 species and
about 10-fold outnumber of host cells. The Bacteroidetes and the Firmicutes are the two major
kind bacteria in the human while Proteobacteria, Verrucomicrobia, Actinobacteria,
Fusobacteria, and Cyanobacteria have small amounts [5, 6]. The composition of gut microbiota
is host specific that can be affected by exogenous and endogenous factors, including gene, diet
and environment. Gut microbiota can be divided into three groups according to their interaction
1

with the host, symbiont, commensal and pathobiont. However, some commensal bacteria can
become pathobiont when their pass through the mucosa barrier [7].
Recently, a large amount of studies has indicated the role of gut microbiota on human
health and disease. The gut microbiota participates in various normal host physiological
activities, from immunity to host metabolism. Besides, gut microbiota can cause different
aliments, including IBD and virus infection [8]. There is immunological equilibrium among
different groups of the gut microbiota to maintain the health status of the host. The dysregulation
of the microbiota can lead to dysfunction of the host. McFarland, L. V. have indicated that
antibiotic therapy could cause diarrhea because the number of Clostridium difficile increased
dramatically after treatment [9]. Several studies revealed that the structure of gut microbiota in
CRC patients is different from the health people and the structural imbalance may contribute to
the progression of CRC [10].
A large amount of studies have indicated that fruits and vegetables in diets can contribute
to the improvement of health and prevention of disease, including cancers and cardiovascular
diseases. Cranberry (Vaccinium macrocarpon Ait. Ericaceae) is a native fruit of North America
that has long been consumed in various products, including juice, jam and dry fruit. Cranberry
has high content of various phytochemical, including flavonoids (flavonols, anthocyanins and
proanhocyanidins(PAC)), catechins and phenolic acids, which bring potential health benefits.
100 g fresh cranberry fruit contains up to 30 mg total phenol content, up to 65 mg anthocyanins.
As the leading fruit sources of A-type linkage PACs, the total PACs content of cranberry on
average is 180 mg per 100 g of fresh fruit weight [11]. In vitro studies demonstrate that cranberry
extract can inhibit proliferation of four human colon cancer cell lines (HT-29, HCT-116, SW480,

2

and SW620), which may be attributed to the synergistic activities of PACs, anthocyanins and
phenolic acids in cranberry [12].
Although polyphenols in cranberry exert the anti-proliferative activity, their absorption
rate in vivo are very low and most of them remain intact when they reach colon where they get
metabolized by gut microbiota. Researches now are interested in the interaction between
polyphenols and dietary fiber and gut microbiota as new therapeutic agents to restore the
microbial balance in several chronic disease [13].
Our long-term goal is to deeply understand the health benefits produced through the
interaction between gut microbiota and various nutrients in whole food. To reach that goal, the
overall objective of this project is to study the impact of cranberry on gut microbiota in different
disease animal model. Our central hypothesis is cranberry is able to exhibit anti-inflammatory
and anticancer activities. Moreover, cranberry will exert the chemopreventive effect through
altering the structure and the function of gut microbiota in mice.
We will test our central hypothesis and achieve our objective by utilizing the following two
specific aims:
Determine the anti-inflammatory effects of cranberry and its impact on gut microbiota on
colitis mouse model.
A dextran sulfate sodium (DSS)-induced colitis mice model will be used to assess the antiinflammatory effect of cranberry in vivo. Histological evaluation will be performed to assess the
colon adenocarcinoma formation and other parameters in DSS–treated mice. Colonic mucosa
will be subjected to immunohistochemical analysis, ELISA analysis to determine the mechanism
of action of cranberry on colon carcinogenesis. DNA of fecal bacteria will be extracted and
undergo 16s rRNA amplicon sequencing to analysis the structure of the bacterial community.
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Determine the anti-carcinogenesis effects of cranberry and its impact on gut microbiota on
colon carcinogenesis mouse model.
An azoxymethane (AOM)/ dextran sulfate sodium (DSS)-induced colitis-associated colon
carcinogenesis mice model will be used to assess the antitumor efficacy of cranberry in vivo.
Histological evaluation will be performed to assess the colon adenocarcinoma formation and
other parameters in AOM/DSS–treated mice. Colonic mucosa will be subjected to
immunohistochemical analysis, ELISA and RT-PCR analysis to determine the mechanism of
action of cranberry on colon carcinogenesis. DNA of fecal bacteria will be extracted and undergo
16s rRNA amplicon sequencing to analysis the structure of the bacterial community.
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CHAPTER 2
LITERATURE REVIEW

2.1 Overiview of colorectal cancer
2.1.1 Cancer progression
Basing on the histological types, cancer can be classified into six major categories:
carcinoma, sarcoma, myeloma, leukemia, lymphoma and mixed types [14]. Carcinoma, which
account for up to 90% of cancer cases, is the accumulation of mutated malignant epithelial cells
[15]. Carcinomas can be developed in different tissues, including head, neck, lung, breast,
bladder, cervix, skin, colon and rectum [16]. Sarcoma are the cancers which develops in
supportive and connective tissues. Cancer from the plasmas cells of bone marrow is classified as
myeloma while leukemia refers to the cancers of bone marrow. Lymphoma are the cancers
which originated in the glands of the lymphatic system.
Hanahan indicated that six principles to characterize a tumor cell: sustaining growth
signals, resisting growth inhibitors, escaping from cell apoptosis, replicating infinitely, inducing
angiogenesis, invading and metastasizing tissues [17]. Evasion from immune system and
deregulation of cellular energetics are two emerging factors of tumor progression for last decade
[18]. The tumorigenic development can be divided into three stages: initiation, promotion and
progression. In the initiation stage, chemical or physical carcinogens induce the mutation of
DNA in cell, which activate the oncogenes and/or inactivate of cell apoptosis genes. The second
stage, promotion, is the immortally replication of mutated cell by external tumor growth
promoter. During last stage, progression, the size of tumor increase continually due to the
invasion and metastasis of mutated cells. Malignant neoplastic changes can be acquired, leading
to the new growth of cancer [19].
5

2.1.2 Introduction of colorectal cancer
Colorectal carcinogenesis is a genetic mutation of single epithelial cell line resulting in the
malignant proliferation of cell and dysplastic appearance in large intestine [20]. The aberrant
crypt foci is first observed during the colorectal cancer progression, indicating that the abnormal
proliferation of crypt cells is associated with the tumor development. Adenomatous polyposis
coli (APC) gene, a potential tumor suppressor gene, is affected in the initiation of colon cancer,
which promote the development polyps and invasion [21]. APC mutation initiates the Wnt
pathway, in which the phosphorylation of β-catenin get inhibited, resulting in the upregulation of
cellular proliferation gene, cyclin D and CD44. P53 gene mutations lead to metastasis while
other additional genetic mutations lead to the growth of colon tumor size [22] [23].
Human colorectal cancer (CRC) is related advancing age, lifestyle and environmental
factors. Since CRC is a complex and multifactorial disease, there is no accurate marker to screen
and monitor CRC which make it difficult to detect and prevent [24].
2.1.3 Introduction of chemoprevention
The increasing amount of cancer case and death around the world throw the emphasis on the
cancer therapy. Basing on the current medical therapy, it is difficult to completely cure cancer.
Although it is possible to decrease the risk of the cancer by avoiding the exposure to dangerous
carcinogens and the other risk factors, it is not easy to eliminate the carcinogens and risk factors
thoroughly from daily life [25].
Targeting on different stages of cancer progression, cancer chemoprevention refers to the
reverse, suppression and prevention of carcinogenic development by using natural, synthetic or
biologic chemical agents [16]. Carcinogenic progression may be retarded when the genotypic
and phenotypic mutation are prevented in different stages. Ample clinical trials suggested that
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some phytochemicals from plants show benefit effect on lowering the cancer risk since they may
interfere the process of cancer progression. However, the molecular mechanisms of
chemoprevention effect of phytochemicals are not well studied.
2.1.4 Molecular mechanisms of chemoprevention
Basing on the affected stage of carcinogenic progression, chemopreventive phytochemicals
can be classified into blocking agents and inhibiting agents [26]. Blocking agents are used to
protect critical cellular molecules, like DNA, RNA and proteins, against carcinogens in initiation
stage while suppressing agents can prevent or retard the stepwise development of initiated cells
in promotion or the progression stage. The chemopreventive agents have influence on many
cellular and molecular activities, including induction of cell-cycle, activation of cell apoptosis,
detoxification of carcinogen, repair of nucleic acid, stimulation of immune system and activation
of tumor inhibitor gene [27].
Mitogen-activated protein kinase (MAPK) pathway is one the common pathway which get
disrupted during cancer progression, leading to the immortal cell proliferation and malignant
growth. Some phytochemicals can suppress the growth signal producing by mutation gene and
control the MAPK pathway to prevent the transformation from epithelia cells to adenoma [28].
The aberrant of some transcription factors have been proved to impact the cancer development.
For example, overexpression of NF-κB may prevent the apoptosis and promote the growth of
cancer cell and phenotypic mutation. Many chemopreventive agents from edible plants can exert
the protective effect through regulating the expression of NF-κB [29]. AP1 can affect cellular
differentiation and replication by modulate the expression of genes [30].
Apoptosis is a natural cellular activity to regulate cell death for eliminate the mutated
cells or aged cells. In cancer progression, the process of apoptosis get suppressed which break
7

the equilibrium between cell growth and death. Chemopreventive phytochemical can re-active
the apoptosis through two different pathways, intrinsic pathway which happen in mitochondria,
exterior pathway which directly modulate the cellular death signal receptors [31]. In extrinsic
pathway, the interaction between tumor-necrosis factor (TNF), or TNF-related apoptosisinducing ligand (TRAIL) and their death receptor, TNF receptor 1(TNFR1) and death receptor 4
(DR4) result in the increasing expression of FAS-associated death domain (FADD) and the
protease caspase 8. Caspase 8 continue to induce caspase 3, leading to the activation of
programmed cell death [32]. In intrinsic pathway, the activation of caspase 9 by the existence of
cytochrome c and apoptotic protease-activating factor 1 (APAF1) give rise to the cell death
response [33].
In addition to these two pathways, several regulators can also be targeted to mediate
apoptosis. p53, which can activate apoptosis and cell-cycle arrest when detect the DNA
mutation, is suppressed in half of cancer types. The interaction between p53 and MDM2
inactivate p53, leading to the deregulation of cell proliferation in cancer development. Therefore,
chemopreventive agents can maintain the activation of p53 to suppress the cancer progression
[34]. β-Catenin is also a targeted protein for phytochemicals . β-Catenin is associated with
tumorigenesis since it is a necessary protein in cell-cell adhesion machinery and WNT signaling
pathway [35].
2.1.5 The role of phytochemicals in cancer prevention and therapy
Epidemiologic evidence that phytochemicals can protects against colorectal cancer is
contradictory. Arthur studied a total 1905 subjects and concluded that a diet with low amount of
fat and high amount of fiber, fruits and vegetables showed no positive effect on preventing the
recurrence of colorectal adenomas [36]. An epidemiologic trial with 1429 subjects was
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conducted by David and indicated that the wheat-bran fiber could not lower the risk of
recurrence of colorectal adenomas [37]. Cascinu indicated that calcium, vitamins A and E
supplement did not protect against the proliferation of colorectal cancer cell [38]. However, J.A.
Baron conducted a epidemiologic trial with 930 subjects who took either calcium carbonate or
placebo for four years and the results suggested that calcium can slightly lower the risk of the
recurrent colorectal adenomas by binding bile and fatty acids [39].
Curcumin is widely studied for its various chempreventive effect, including anti-oxidative ,
anti-inflammatory and anti-cancer effects. Plummer indicated that curcumin can decrease the
expression level of cyclooxygenase-2 (COX2) and NF-κB by reducing the amount of NF-κBinducing kinase (NIK) in human colonic epithelial cells [40]. Singh reported that curcumin can
prevent phosphorylation and degradation of IκB in human myeloid leukemia cell line which lead
to the suppression of DNA translocation and mutation [41]. Epigallocatechin gallate (EGCG) is
one kind of tea polyphenols which is extensively investigated for its anti-carcinogenic effects on
different tissues, including colon, liver, pancreas, lung and skin in rodent animals. Yoshizawa
and his colleagues successfully suppressed the tumor development in DMBA-initiated mouse
skin with EGCG. Metz described that oral administration of green tea extract can inhibit the
expression of COX2 in intestinal mucosa in azoxymethane induced colonic adenoma rat models.
The studies of Gong indicated that EGCG can protect liver from malignant mutation in rats [42].
Resveratrol is a stilbenoid which can be found in the skin of grapes, blueberries and rasberries.
The health benefits of red wine are mainly attributed to the presence of resveratrol, including the
protective effect from cardiovascular disease and cancer. Studies showed that resveratrol can
induce apoptosis and downregulation of NF-κB in both human pancreatic cancer cell lines and
breast cancer MCF-7 cells [43, 44].
9

2.2 Overview of inflammation
2.2.1 Introduction of inflammation
Inflammation is non-specific immune response of body to injury, pathogens or harmful
chemicals, which may lead to hyperemia, increasing blood flow and the molecular mediators and
vasodilatation [45]. The process of inflammation manage to get rid of the stimuli which cause
cellular damage, the injured or aberrant cells or tissues and activate the repairing process of
body. The inflammation of body is mainly produced through two ways, innate immune response
and adaptive immune response. Through pathogen-associated molecular patterns (PAMPs) and
other cell products related to system defenses, the innate immunity show a quick reaction to the
extrinsic chemicals which commonly exists on pathogens while the adaptive immunity only
response to chemicals with specific structure [46]. When the innate immunity recognize the
"invasive" agents, macrophages, a type of white blood cell, are generated to eliminate the
chemicals or cells without healthy protein marker on the surface. In order to identify stimuli,
macrophages can use different scavenger receptors and Toll-like receptor which can pair many
pathogenic molecular like lipopolysaccharides. The interaction between Toll-like receptors and
their ligands can activate the NF-κB and MAPK pathway [47]. In contrast, the adaptive
immunity produce various antigen receptors like T-cell receptors which can bind with certain
molecular structures to identify the specific targets. The ligations of targets and T-cell receptors
can stimulate the immune system where the cytotoxic T-cells are generated to eliminate the
targets and B-cells to produce antibody [48].
Despite its protective effects, a lot of chronic diseases such as arthritis, diabetes,
cardiovascular disease, cancers and bowel diseases, can be attribute to inflammation when the
inflammatory process get deregulated. Both innate and adaptive immune responses target on
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either epithelial cells or mesenchymal cells on various organs, modulating the cellular activities
of tissues, including the activation of leukocytes and the programmed cell death process, which
result in the dysfunction of tissues. Through disordering the normal function of epithelial cells
(i.e. endothelial cells, enterocytes), inflammatory process can initiate and promote diseases [46].
2.2.2 Introduction of inflammatory bowel disease
In United States and Europe, there are total 3.6 million people suffering from
inflammatory bowel disease (IBD). Besides, the incidence and prevalence of IBD are increasing
in both developed countries and developing countries which rise serious attention to this disease
[49]. Inflammatory bowel disease includes two major types, ulcerative colitis (UC) and Crohn’s
disease (CD), which refers to the aberrant inflammation in small intestine and colon. Although
UC and CD are two different diseases, the symptoms of these two diseases are similar, including
abdominal pain, vomiting, diarrhea with blood [50]. Ulcerative colitis mainly happen in the
colon and affect the superficial mucosal layers where severe ulceration take place and
neutrophils assemble in the crypts. However, Crohn’s disease can have impact on the whole
gastrointestinal tract in which aggregated macrophages constitute granulomas. Crohn’s disease
mainly happen in ileum and the tissue damage is normally first found on Peyer’s patches [51].
2.2.3 Risk factors to inflammatory bowel disease
According to the epidemiological studies, inflammatory bowel disease can be affected by
different factors such as environmental factors, diet and genetic difference. The Halfvarson’s
study on twins with Crohn’s disease indicated that genetic difference played an importance role
on the disease incidence [52]. Cigarette smoking is one of the most significant environmental
factors for inflammatory bowel disease even though the impact of cigarette smoking on
ulcerative colitis and Crohn’s disease are different. A study of 400 participants pointed out that
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smoking exert protective effect against ulcerative colitis while no adverse effect on Crohn’s
disease [53]. Silverstein conducted a case control study on cigarette smoking and ulcerative
colitis and reported that non-smoking patients is more likely to have ulcerative colitis comparing
with patient who smoke [54]. Another case control study including 84 smoking patients and 84
non-smoking patients showed that smoking can lower the risk of ulcerative colitis of patients
[55]. Several trials used transdermal nicotine as therapy for ulcerative colitis which suggested
that the treatment of nicotine did not contribute to the remission rate but introduced other side
effects to the participants [56] [57]. It is still unclear the interaction among cigarette and smoking
and ulcerative colitis and the potential explanation for the unusual finding is that the multiple
compounds of cigarette generate the complex effect. Despite the potential beneficial effect on
ulcerative colitis, cigarette smoking has been proved to increase the risk of Crohn’s disease [58].
Appendectomy is another importance environmental factor for inflammatory bowel
disease. Studies reported that appendectomy can protect against ulcerative colitis while promote
the Crohn’s disease [59]. Koutroubakis et al. analyzed 17 studies with about 8000 participants
and concluded that appendectomy dramatically decrease the risk of ulcerative colitis [60]. The
epidemiological study of Andersson reported that appendectomy have adverse effect on Crohn’s
disease in large Swedish cohorts [61]. The possible mechanism of the different effect of
appendectomy on two types of inflammatory bowel disease is the development of ulcerative
colitis can be inhibited by the inflammation in appendix while Crohn’s disease can be promoted
through the inflammation.
Diet also plan an important role in the development of inflammatory bowel disease. The
incidence rates and prevalence of inflammatory bowel disease are significantly higher in several
geographic regions including northern Europe, United Kingdom and North America than others,
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which is mainly affected by the different diet [62]. The consumption of sugar in diet was
extensively studied for its adverse effect on inflammatory bowel disease. Russel have conducted
a case control study and reported that excessive intake of food with high amount of sugar can
increase the risk for the inflammatory bowel disease, especially Crohn’s disease [63]. Riordan et
al. have reviewed that the carbohydrate consumption was risk factors for Crohn’s disease [64].
However, whether the increasing consumption of dietary fiber, fruit or vegetable can prevent
inflammatory bowel diseases is still inconclusive since the intake amount may be confined due to
the situation of patients.
2.2.4 The relationship between inflammatory bowel disease and colon cancer
Many studies suggested that chronic intestinal inflammation can promote the progression
of colon cancer since the presence of colitis is proved to contribute to cancer development and
the anti-inflammation drugs like 5-aminosalicylates can protect against the colon cancer. The
sporadic colon cancer share the same pathway with colitis-associated colorectal cancer which
result in the mutation of DNA and cellular damage [65]. The chromosome instability caused by
inflammatory bowel disease can initiate the colorectal cancer, which can be affected by several
factors, including the duration time of colitis, the affected area on colonic surface area [66].
Unlike sporadic colorectal cancer, colitis-associated colorectal cancer is initiated on multiple
aberrant adenomatous polyposis coli (APC) and conquer larger surface area of mucosa.
The loss of p53 gene in the chromosome mutation is suggested to be the critical risk
factor for the development of colitis associated colorectal cancer [67]. Epidemiological studies
showed that the mutation of p53 in mucosa of ulcerative colitis patients was much more common
than the normal people, implicating that chronic intestinal inflammation associated with the early
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stage of colon cancer progression [68]. Besides, the increasing oxidative stress in inflammatory
bowel disease contribute to the growth of tumor.
2.2.5 The role of phytochemicals on inflammatory bowel disease prevention and therapy
Many phytochemicals are considered to have ability to protect against inflammatory bowel
disease, including flavonoids, polyphenols and dietary fibers. Flavonoids which are abundant in
various fruits, vegetables and plants are widely studied for their anti-oxidative and antiinflammatory effect in cell model and animal model [69]. Galvez et al. induced colitis in rats
which received normal diet mixing with rutin, a common flavonoids in wheat, tomatoes and
apricots. The study indicated that rutin can inhibit the inflammation and mucosa lesion by
modulating the levels of interleukin (IL-1), IL-6, iNOS, and tumor necrosis factor α (TNF-α)
[70]. Polyphenols ubiquitously present in the plant and are excessive studied for their multiple
biological activity. Green tea polyphenols are the most common studied compounds for their
strong anti-oxidative effect. Several studies reported that the activity of NF-κB and kinases
which associated with the inflammatory process were inhibited by the green tea polyphenols and
contribute to the inflammatory bowel disease prevention [71]. Catechins are one group of
polyphenols which were reported to lower the risk of inflammatory bowel disease through
modulating the inflammatory cytokines in both in vitro and in vivo studies [72]. Curcumin is
natural phenols which widely distributed in ginger and certain spice. Studies indicated that
curcumin interrupt the activation and transcription of COX-2, lipoxygenase and NF-κB, leading
to the amelioration of mucosal inflammation [73]. Dietary fiber not only can modulate various
inflammatory mediator such as TNF-α, IL-2 and nitric oxide, but also can interact with
microorganisms which can produce short chain fatty acid to protect against the inflammatory
process [74].
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2.3 Overview of gut microbiota
2.3.1 Introduction of gut microbiota
Microorganisms ubiquitously distribute in the environment where human body can easily
access to. Although the previous studies mainly focused on the extrinsic microorganisms which
can cause human disease or their various function, more and more researches started to concern
the microorganisms in/on human body [5]. The number microorganism in/on human body is
about 1014 times more than that of human cells, which suggested that the microorganisms have a
significant interaction with human body. It is estimated that more than 70% of microorganisms
flourish in the colon in which microorganisms can get enough nutrients and space for their
growth while the others can be founded on skin, stomach, respiratory tracts and urinary tract
[75].
Gut microbiota refers to the microorganisms that live in the gastrointestinal tract, which
contains approximately 66% anaerobic bacteria and 34% facultative aerobic bacteria and aerobic
bacteria [76]. Human gut microbiota is composed of seven bacterial phyla, including
Bacteroidetes, Firmicutes, Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, and
Cyanobacteria, of which Bacteroidetes and Firmicutes account for the majority. According to the
multiple studies on the sequencing of gut microbiota, more than 500 species are identified in the
colon, suggesting that the large diversity of microorganisms [77]. O'Hara et al. reported that
amount of microorganisms are not equally distributed in the whole gastrointestinal tract. It is
estimated that less than 104 bacteria per gram in the upper gastrointestinal tract while about 1012
bacteria in the lower gastrointestinal tract (Fig. 2.1A) [5] [78]. In addition to the quantity of
bacteria, each part of gastrointestinal tract is occupied by different kinds of bacteria. A study
analyzed the composition of bacteria in small intestine and colon and concluded that the majority
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bacteria phyla in small intestine are Firmicutes and Actinobacteria while the Fimicutes were
enriched at colon [79]. The colon is constituted by three different parts, epithelial surface,
mucosa and intestinal lumen, in which the types of flourishing bacteria are different. Swidsinski
et al. indicated that Bacteroides, Streptococcus, Bifidobacterium only present in the feces (Fig.
2.1B) [5] [80].
Human gastrointestinal tract acquires bacteria through different ways. At birth, the gut
microbiota mainly come from mother’s canal where the composition of gut microbiota is similar
to colon. If the infant is delivered by cesarean section, both the diversity and the quantity of the
gut microbiota would dramatically reduce due to the lack of exposure to mother’s gut microbiota
[81]. After birth, the composition of gut microbiota get shaped easily by the diet and
environment but become stable after 1 year old (Fig. 2.1C) [5].

Figure 2.1 Summary of the introduction of human gut microbiota. A: the composition and
quantity of gut microbiota on different sites of the gastrointestinal tract. B: the composition in the
different parts of intestine. C: the factors for shaping microbial composition
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2.3.2 The function of gut microbiota
The role of gut microbiota in nutrition and health of mammalian host is the result of the
long time adaption and coevolution. In order to maintain the symbiosis relationship with gut
microbiota, the immune system not only need to control the population and the activity area of
bacteria, but also restrict the immune response to endure the growth of bacteria Gut microbiota
not only can induce the immune response of the host, but also can offer nutrients through their
various activities, which are the mainly function of gut microbiota [82].
The presence of gut microbiota can modulate the immune system and contribute to the
immunological development. Gut microbiota is considered as the extrinsic “organ” by the
immune system, which can continually trigger the immune response to protect the host.
Macpherson and Harris conducted an experiment on germ free mice and reported that the
immune system of germ free mice was not fully developed. For example, the germ free mice
have less amount and types of immune cells comparing with the normal mice. The formation of
the organs associated with immune system such as spleens and lymph nodes did not fully
complete, resulting in the function deficiency [83]. Another study indicated that germ free
animals were not capable to produce enough CD4+ T cells, whereas the treatment of
polysaccharide of bacteroide fragilis can trigger the proliferation of CD4+ T cells and formation
of spleen white pulp [84]. The family of Lactobacilli spp. can affect the activation of various
cytokine and immune cells through modulating the differentiation of dendritic cells [85].
Gut microbiota can also protect the host against the invasive pathogens. A large number
of bacteria colonize on the surface of intestinal mucosa which form a natural barrier between
mucus surface and extrinsic bacteria, especially the pathogen [86]. Besides, gut microbiota can
induce the immune system to generate different antimicrobial peptides, including defensins,
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cathelicidins and C-type lectins, which can interact with gut microbiota to modulate their growth
and composition [87]. Cash and colleagues reported that the complete composition of gut
microbiota can trigger the production of antimicrobial peptides in paneth cells while the gut
microbiota with low diversity may not activate the same function or induce the low intensity
production [88]. Lopez et.al even pointed out that the presence of B. thetaiotaomicron can
stimulate the production of matrilysin, leading to the increasing activation of defensins [89].
Many studies have indicated that probiotics have protective effect against various pathogens. For
example, an in vitro cell cultures study reported that Lactobacillus and Bifidobacterium can
inhibit the Listeria infection by the metabolites and interaction of immune response [90]. Studies
also pointed out that lactic acid produced by the commensal bacteria can prevent the growth of
pathogens [91].
In terms of metabolic ability, gut microbiota contribute to the host through providing
nutrients and further processing xenobiotic which cannot be digested by the host. Jeremy and
colleague reviewed that germ free animal gained less weight than normal animal with the same
amount of food consumption [92]. The possible mechanisms is that gut microbiota can extract
extra calories by utilizing indigestible compounds as well as increase the absorption rate of the
nutrients by promoting the absorptive ability of intestinal epithelium. For instance, gut
microbiota can digest dietary fiber, polysaccharide to short chain fatty acid, monosaccharide
respectively, which can be utilize by the host (Fig 2.2) [93]. Short chain fatty acid is one of the
most important metabolites of gut microbiota which is not only the energy source for the host,
but also can suppress the production of toxic metabolites and the proliferation of various types of
pathogen. Besides, gut microbiota can interact with lipid absorption and deposition through the
augmenting the secretion of lipoprotein lipase in the gastrointestinal tract [94].
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Figure 2.2 Microbial metabolic pathway of dietary fibers

2.3.3 The role of gut microbiota in colon cancer progression
Although gut microbiota bring several important benefits to the host, it also have harmful
effects on human health since not all the bacteria are commensal to the host. Many studies
indicated that gut microbiota is the risk factor for carcinogenesis through different mechanisms
[95]. Some species of bacteria can stimulate the excessive proinflammatory signaling at the
intestinal mucosa which will lead to the damage of intestinal epithelium and the initiation of
colorectal carcinomas. Besides, bacteria itself is toxic to the intestinal epithelium or induce
toxicity through host cells to tissue. Moreover, some groups of bacteria can transform the
nutrients to the toxic product which can promote the neoplasia by damaging the intestinal mucus
layer and inducing the repair process.
According to the several epidemiological studies, the composition of gut microbiota in
colorectal carcinogenesis patients were significantly different from that in the health person.
Moore reported that the number of family of Bacteroides and Fusobacterium spp. enriched in the
patients with colon cancer, suggesting that the decreasing diversity of the gut microbiota. In
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health person, the majority of gut microbiota are the family of Lactobacillus spp.and
Eubacterium aerofaciens, which can produce short chain fatty acid to protect the host against
pathogen [96]. The studies implicated that the presence of several species of gut microbiota may
be in favor of the progression of colorectal carcinoma. In contrast, Manoj et al. indicated that
probiotic (such as bifidobacteria and Lactobacillus spp) and its metabolites may plan an role on
cancer prevention through the ability to eliminate the carcinogen [97].
2.3.4 The role of gut microbiota in inflammatory bowel disease development
Inflammatory bowel disease is caused by the excessive immune response in
gastrointestinal tract, which can be attributed to several reasons. Gut microbiota is generally
suspected to be one of the risk factors for the development of intestinal bowel disease, especially
Crohn’s disease. Several epidemiological studies reported that antibiotic treatment could
significantly attenuate the inflammatory lesion in inflammatory bowel disease patients,
suggesting that the activity of gut microbiota may stimulate the over expression of proinflammatory cytokines [98]. Multiple animal studies also revealed the relationship between gut
microbiota and inflammatory bowel disease. Sellon et al. indicated that the development of
intestinal inflammation was prevented in interleukin- 10- (IL10-/-) mice in germ-free state while
severe colitis presented in conventional environment [99]. Kent et al. described that the intestinal
colitis in rats could be reversed by the usage of antibiotics [100].
The composition of gut microbiota is proved to play an important role in the development
of intestinal colitis. Tbx21–/–Rag–/– mice lost the ability to modulate and develop their immune
system, which are prone to acquire severe colitis. Garrett et al. reported the health state of Tbx21–
/–

Rag–/– mice can be restored after treating with antibiotic, proving that the cause of colitis in

mice is gut microbiota. Moreover, the translocation of gut microbiota from Tbx21–/–Rag–/– mice
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with intestinal inflammation disease to wild-type health mice resulted in the development of
colitis in wild-type mice, indicating that the certain species of bacteria are the stimuli to the
intestinal inflammation [101]. Although the types of bacteria involved in the development of
inflammatory bowel disease are still under investigation, several studies pointed out the presence
of pathogenic E.coli was strongly associated with intestinal inflammation (Fig 2.3) [5]. In
contrast, when severe colitis induced in mice, some bacteria in gut secreted vitamin D to protect
against the inflammatory process, which may be the reaction of bacteria to the growth
suppression producing by the inflammation [102]. Sokol et al. reported that F. prausnitzii has the
ability to modulate the pro-inflammatory cytokines and restore the immunological equilibrium of
the host [103].

Figure 2.3 The interaction between pathogenic E.coli and the immune system
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2.4 Cranberry and its phytochemicals
2.4.1 Introduction to cranberry
A large amount of scientific evidence proved that fruits and vegetables comsumption not
only offer necessary nutrients to human body, but also maintain the health condition and protect
body against various diseases. It has been confirmed that cardiovascular disease, colon cancer,
Alzheimer’s disease and obesity can be prevented through increasing intake of fruits and
vegetables [104]. It is believed that the phytochemicals in fruits and vegetables such as
flavonoids, phenolic compounds, stilbenes and carotenoids, plan an important role in the disease
prevention [105]. Some of the phytochemical compounds are strong anti-oxidative agents which
can inhibit with excessive oxidative process in the body to exert their protective effect. Others
which do not possess the anti-oxidative ability may affect the disease pathway, the activity of
microorganisms and the expression level of transciptor to modulate the development of disease
or the immune response [106].
Cranberry (Vaccinium macrocarpon) is a kind of native American fruit, which has been
consumed as food for a long time. Cranberry jam is a traditional food served in Thanksgiving
meal in United States and widely consumed in north Europe [107]. In United States, the total
cranberry crop was up to 8.6 million barrels, which value for 300 million dollars in 2014 [108].
The large consumption of cranberry is not only attributed to the good flavor and taste of
cranberry but also to their potential health benefits. Cranberry juice has been used as the
traditional treatment for urinary tract infections in woman for centuries, which believed to be the
effect of one of its unique phytochemicals, proanthocyanins [109]. Recently, cranberry has been
widely studied for its nutrition and strong anti-oxidative effect. It is believed that
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phytochemicals of cranberry may be the natural chemopreventive agents to several diseases,
such as pathogen infection, inflammation and cancer.
2.4.2 Major phytochemicals of cranberry
Cranberry is rich in various kinds of phytochemicals, including anthocyanins,
proanthocyanins, phenolic acids and triterpenoids [110]. Anthocyanins is the major pigments of
cranberry, which bring the red color to the ripe cranberry fruit. 100 g cranberry fruits can contian
up to 140 mg anthocyanins, while the processing of cranberry juic would lost 90% of
anthocyanins [111]. Wu et al. reported that thirteen types of anthocyanins (Table 2.1) were
founded in freeze dried cranberry sample through LC-MS/MS, of which more than 95% are the
basic backbone strutures with cyanidin and peonidin [112]. Mulleder et al pointed out that
anthocyanins with glycosides would be easier to get absorbed by the body than the anthocyanins
with other strutures, suggesting that the cranberry anthocyanins are the great source for
anthocyanins intake [113].
Table 2.1 The strucures of anthocyanin
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Proanthocyanins (PACs) are a group of oligomers or polymers of flavan-3-ols, which have
large molecular weight and many free hydroxyl groups. 100 g fresh cranberry fruits contain up to
418 mg PACs, which is much higher than the other commonly consuming fruits [114]. Due to
their complicated structure and similarity, PACs in cranberry cannot be completely separeted and
identified through current analysis method. Among the known struture of PACs (Fig 2.4) in
cranberry, the majority of PACs are procyanidin A2 which has A-type linkages while
procyanidin B2 with B-type linkages accounts for less than 10% [115]. Besides, A-type
procyanidin is only found in cranberry fruit, indicating that cranberry is the best food source for
this phytochemicals.

(B)

(A)

Figure 2.4 The structures of cranberry proanthocyanins: (A) procyanidin B2 (B) procyanidin A2
Ample kinds of phenolics and benzoates are found in the cranberry which contribute to the
unique aroma of cranberry as well as the strong antioxidative activity. However, most of
phenolics and benzoates in cranberry are binding with different compounds instead of free form.
For example, Zuo et al. reported that many phenolics form a linkage with multiple
polysaccharide like celluose in cranberry to increase the stability [116]. Chen et al. further
quantified the amount of phenolics and conlcused that about the amount of bound phenolics in
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cranberry was three times more than the free phenolics after, indicating the importance of bound
phenolics in further study [117].
Terpenes and their derivatives which contribute to the odors of most of food also present in
cranberry. The most recognized terpenes in cranberry is ursolic acid (Fig 2.5), a pentacyclic
triterpene. The concentration of ursolic acid can be up to 110 mg in every 100 g cranberry fruits
[118]. Huang et al. indicated that ursolic extracted from cranberry can mediate the expression
level of pro-inflammatory cytokines, suggesting that the potent health benefits from cranberry
may partly come from ursolic acid [119].
Flavonols is another group of compounds which is enriced in cranberry fruits. Quercetin,
myricetin and their derivatives are the major flavonols in cranberry (Fig 2.5) [106]. Vvedenskaya
et al. reported in total 22 kinds of flavonls was found in freeze dried cranberry powder, some of
which have unique struture [120]. In addition to its ample diversity, the content of total flavonls
in cranberry was really high, which was up tp 400 mg/kg, suggesting the potential health
beneficial effect.

(A)

(C)

(B)

(C)

Figure 2.5 Structures of (A) ursolic acid (B) quercetin (C) myricetin in cranberry
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2.4.3 The health effects of cranberry and its phytochemicals
Many studies indecated that the intake of cranberry r the phytochemicals extracted from
cranberry can lead to several health beneficial effects which can be divided into two catorgries,
pathogen inhibition and disease prevention.
Cranberry have long been used to treat the urinary tract infections which are mainly happen
in women. It is reported that about 11 million women get the urinary tract infections every year
and nearly one in five cured women re-gain the infections in 6 month [121]. The high incidence
and recurring rate rise the attention to cranberry as it is a traditional folk remedy to urinary tract
infections. Bailey et al. conducted a clinical study on the effect of creanberry extract on
preventing urinary tract infections in women, which proved that the consumption of cranberry
extract can lower the recurrent rate [122]. Stother reported the similar inhibition result by using
cranberry powder, suggesting that the protective effect of cranberry agasint urinary tract
infections was reliable [123]. Kontiokari et al. also pointed out that cranberry juice comsumption
significantly decrease the incidence rate of urinary tract infection of 300 women [124]. Although
cranberry can prevent the adult women from contracting the urinary infection, their effect on
reversing the infection is barely confirmed by the clinical studies, indicating that cranberry can
be used as prophylactic for urinary tract infections for women. Urinary tract infections is mainly
cause by Escherichia coli, which is difficult to elimminate by using antibiotic since Escherichia
coli can endure the presence of antibiotic after recurrence [125]. However, Gupta et al. indicated
that cranberry prevent the adherence of E.coli to urinary tract instead of killing the bacteria,
leading to the better way for infection prevention [126]. A-type proanthocyanins and the high
acid content of cranberry are believed to be the two major phytochemicals that suppress the
adhesion of E.coli [109].
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In addition to the prevention on the urinary tract infection, cranberry also suppress the
infection of other organs. Study showed that gastrointestinal disease caused by the Helicobacter
pylori infection can be prevented by cranberry [127]. Cranberry prevent the infection through
reducing the attached h.pylori to the epithelia surface of stomach. Burger et al. reported that
cranberry extraction of compounds with high molecular weight exerted the anti-adhesion effect
on h.pylori [128]. Accumulated evidence and studies suggested that phytochemicals in cranberry
can be used to inhibit bacterial infection in the mouth, and therefore protect against dental caries
and periodontal disease. Duarte et al. reported that cranberry proanthocyanins and flavonol can
suppress the formation of pathogenic biofilm and reduce the infection [129]. Labrecque et al.
indicated that the growth of several pathogen such as Porphyromonas gingivalis and Treponema
denticola in mouth can be inhibited by the administration of cranberry extraction [130].
Due to their strong anti-oxidative effect, cranberry and its phytochemicals is believed to
have potent anti-inflammatory activity and anti-cancer activity. Kandil et al reported that
cranberry proanthocyanins can inhibited the activity of ornithine decarboxylase, which is one of
the regulator of tumor suppression pathway [131]. Youdim et al. indicated that cranberry
anthocyanins can mediate the expression of TNF-α and other cytokines to control the
inflammation process in microvascular cells [132]. A review summarized the in vitro anti-cancer
study on cranberry and conclude that phytochemicals in cranberry can be a possible
chemopreventive agents for various cancer [12]. With the concentration as low as 20 µg/mL,
proanthocyanins in cranberry can inhibit the growth of various types of cancer like breast and
colon cancer. The concertation for ursolic acid and quercetin to show suppression effect on
cancer cells were a 42 µg/mL and 20 µg/mL, respectively. Although the in vivo studies on the
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beneficial effects of cranberry are contradictory, it is important to further study the potent
mechanism of the health benefits of cranberry phytochemicals.
2.4.4 The bioavailability of cranberry and its phytochemicals
Bioavailability refers to the absorption rate of nutrients in the body, which can be measured
by the concentration of the nutrients. The bioavailability is important for evaluating the
bioactivity of nutrients in vivo study since the nutrients must be absorbed and delivered to
targeted sites in order to exert their ability. The reason why in vitro studies and in vivo studies
may have different result on the function evaluation of phytochemicals is the difference of the
absorption rate in vitro and in vivo. Ample emerging studies focus on the bioavailability of
cranberry phytochemicals (Table 2.2), indicating that the huge difference of bioavailability
among various types of phytochemicals [106].
Table 2.2 Bioavailability of cranberry phytochemicals

ND = not determined
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Cranberry proanthocyanins have the poorest absorption rate comparing to all the
phytochemicals due to its large molecular weight and complex structure. It is suggested that the
proanthocyanins have the ability to denature protein and cause potent adverse effect on body,
resulting in the resistance on absorbing [133]. Deprez et al. reported that only proanthocyanins
oligomers can be absorbed directly by the body while polymers go through degradation and
digestion by gut microbiota in colon [134]. The metabolites of proanthocyanins with small
molecular weight can be easily absorbed and exert different beneficial effects.
Anthocyanins is another poor absorbed phytochemicals in cranberry. Andres et al.
indicated that small portion of anthocyanins can pass the brain barrier and get to brain, which
offer a new sight for brain disease treatment [135]. Flavonols and phenolic acid have much
higher bioavailability. Pedersen reported that the concentration of phenolic acid went up to 600
mg/L gallic acid equivalents in human plasma and most of them excreted through urine after
consuming cranberry juice. The high content of phenolic acid in urine may contribute to the
protective effect on urinary tract infection.
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CHAPTER 3
INTERACTION BETWEEN CRANBERRY AND GUT MICROBIOTA AND ITS
IMPLICATION ON ANTI-INFLAMMATION
3.1 Introduction
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) or ulcerative colitis
(UC), which will lead to the epithelial dysfunction or increasing mucosal permeability, are
prevalent in western countries, including western Europe and United States. It is estimated that
1.4 million patients are suffering from the IBD while $6.3 billion is used for the treatment of
IBD annually [136]. Environmental factors like western diet and smoke are suspected for the
major cause for the IBD, leading to alteration of the microbial structure and function in the IBD
patients. In distal ileum and colon, microbiota have extraordinary interaction with the host’s
epithelial cells and mucosal immune system, which will affect host physiology, metabolism,
nutrition and immune function. Microbiota and the immune system in the intestine form a
homeostasis to maintain the health status of the intestine. However, the disruption of homeostasis
will bring significant influences on both the host and the gut microbiota [137]. Abundant clinical
and laboratory research has showed that intestinal inflammation responses are the protective way
of body to eliminate the commensal bacterial which have pathogenic potential [138].
Whole cranberry fruit have large amount of polyphenols and dietary fiber which cannot
get absorbed and digested in the body. When they reach colon nearly intact, gut microbiota plays
a significant part on the depolymerization and metabolizing. Cranberry have been widely studies
for its anti-microbial, anti-adhesion and antioxidant properties. In vitro researches have indicated
that cranberry juice can be a promise treatment for oral infections and urinary infections [139].
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Xian et al. reported that several phytochemical such as ursolic acid, quercetin and flavonol can
suppress oxidative stress in the cell with EC50 values as low as 10µM [110]. However, due to the
low bioavailability of various polyphenols in cranberry, the bioactivity of cranberry is largely
influenced by the degradation process of gut microbiota. To date, the interaction between
cranberry and gut microbiota have not been published.
Meanwhile, the structure and function of the gut microbiota are expected to alter in
response to the digestion of cranberry. Wang et al. reported the composition of gut microbiota in
mice can be mediated by dietary polysaccharides and short chain fatty acid production, resulting
in the attenuation of intestinal coliis [140]. Microbial activity plays a significant role on
maintaining the physiological functions of colon and regulating the immune system [141]. It is
known that probiotic in the gut can protect human from the process of inflammation while a
great number of pathogens or pathogens-like species can cause the diseases due to their ability to
produce toxin or stimulated agents. Accumulating experimental evidence indicated that the
increasing amount of pathogen in colon is associated with the development of the inflammatory
bowel diseases (IBD) [142]. Helicobacter pylori is the example for the potentially harmful
microbe, which can induce chronic gastric inflammation and cancer [143]. E.coli has been
studied widely for its pro-inflammatory effect in multiple animal models. Janelle et al. indicated
that the presence of Enterobacteriaceae in Il10-/- mice can stumulate the inflammation and
further promote the tumor development [144].
Besides, using their typical enzymes, gut microbiota can metabolize a large amount of
substrates, like dietary fiber which can provide various health benefits. Valcheva et.al indicated
that the increasing number of Lachnospiraceae and Ruminococcaceae resulted in the increasing
production of short chain fatty acid like butyrate and acetate, which protect the mediate the
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microbial translocation and inflammatory pathway [145].Therefore, modulation of the gut
microbiota may be the possible way to improve the intestinal health and immune system. This an
innovative work that was planned to understand the role of the cranberry and gut microbiota on
anti-inflammatory effect through both mouse model. The molecular mechanism of the antiinflammatory effect were investigated to explain the correlation between the host and them.

3.2 Materials and Method
3.2.1 Animals, diets and experimental procedure
The protocol for the animal experiment was approved by Institutional Animal Care and
Use Committee of University of Massachusetts Amherst. 40 male wild-type CD-1 mice (6-8
weeks old) were obtained from Charles River Laboratories (Wilmington, MA, USA). The mice
were divided into 4 groups (n=10 per each group) to receive either standard chow (AIN93G diet)
or cranberry diet. Cranberry diet is made of AIN93G diet and 1.5 % (w/w) freeze dried whole
cranberry powder. 5 mice were kept in a cage in animal facility where the environment
maintained constant temperature (23°C) and humidity (65%). After one-week diet acclimation
with respective diet, the four groups were distributed as follows: the control group, which was
fed with standard chow and regular water; the DSS group, which received the standard diet and
1.5 % DSS water (wt/v, dextran sulfate sodium salt, average molecular weight 36,000–50,000)
(International Lab, Chicago, IL, USA); the control-cranberry group, which received the
cranberry diet and normal water; the DSS-cranberry group, which received the cranberry diet and
1.5 % DSS drinking water (wt/v). All experimental groups will be provided with respective
drinking water ad libitum for 4 days and received the normal water for 7 days for total 4 cycles
(Fig. 3.1). The weight of the mice were recorded every other day during the whole experiment.
At the end of the third cycles of DSS water treatment, all mice were sacrificed by CO2
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asphyxiation. The colons were removed from the body and got cut longitudinally to clean up the
feces pellet. The weight and the length of the colon then were measured and recorded. After
measurement, the whole colon were cut into two part longitudinally and kept separately by two
ways for further analysis. One part of the colon were stored at -80°C for ELISA analysis while
the other part were first fixed in 10% buffered formalin (pH 7.4) for 24 h and replaced by
methanol for long term storage and further histopathological and immunohistochemical analysis.
The feces pellet were collected from the colon and stored at -80°C for further sequencing
analysis. Both the liver and the spleen were dissected from the body and weighted for evaluation
of disease progression of ulcerative colitis.

Note: Black shade represents 1.5% DSS water treatment
Figure 3.1. Animal experimental design
3.2.2 Disease activity index (DAI) and histological evaluation of the colon
Disease activity index were determined basing on the scoring for weight loss, stool
consistency and rectal bleeding, which were recorded every other day (Table 3.1a) [146]. The
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fixed colon segments were first dehydrated by using ethanol and isopropanol, then get embedded
in paraffin wax. The wax specimen were sectioned into slides which get stained by hematoxylin
and eosin (H&E). Histological grading was evaluated basing on the inflammatory criteria (Table
3.1b) [147].
Table 3.1a Scores of Disease Activity Index (DAI)
Score

Body weight loss (%)

Stool consistency

Fecal blood

0

None

Normal

None

1

1~5

Soft but form

Hemoccult+

2

5~10

Soft

Blood

3

10~20

Diarrhea

Gross bleeding

4

>20

Table 3.1b Histological scores
Score

Severity of
inflammation

Extent of
inflammation

Crypt damage

0

None

None

None

1

Mild

Mucosal

Basal 1/3

2

Moderate

Mucosal
and
submucosal

Basal 2/3

3

Severe

Transmural

4

Cryps lost but suface epithelium present
Crypts and suface epithelium lost
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3.2.3 Enzyme-linked immunosorbent assay (ELISA)
Intestinal mucosa were removed and bead homogenized in phosphate buffer (PBS)
solution ( 0.4 M NaCl, 0.05% Tween-20, 0.5% BSA, 0.1mM benzethonium, 1% protease
inhibitor cocktail (Boston Bioproducts, Ashland, MA, USA)). After homogenization, the
samples were centrifuged at 10,000g for 30 min at 0°C to collect the supernatant. The
supernatant samples were loaded in sandwich enzyme-linked immunosorbent assay (ELISA) kits
to determine the concentrations of IL-4, IL-13, IL-1β, IL-6, and TNF-α [147].
3.2.4 Isolation of DNA
Fecal pellets were collected from the mice colon to assess gut microbiota. Bacterial DNA was
isolated from feces by using PowerFecal DNA isolation kit (MoBio Laboratories, Inc., Carlsbad,
CA) according to the manufacturer’s protocols.
3.2.5 16S rRNA analysis
The concentration of the DNA samples was measured by NanoDrop Spectrophotometer (Thermo
Scientific, Waltham, MA, US). PCR was performed to amplify the 16s rRNA gene marker using
region of interest-specific primers with overhang adapters attached, which of sequences are: 16S
Amplicon PCR Forward Primer =
5'TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG) and
(16S Amplicon PCR Reverse Primer =
5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC)
[148]. 2x KAPA HiFi Hotstart ReadyMix (KAPA Biosystem, Wilmington, MA, US) was used as
PCR reagent. Then PCR product was cleaned and purified by using AMPure XP beads
(Beckman Coulter, Danvers MA, US). A second PCR was performed to attach dual indices and
Illumina sequencing adapters using the Nextera XT Index Kit (Illumina, San Diego, CA, US)
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followed by AMPure XP bead purification. The quantity of PCR products was determined by
using Qubit dsDNA BR Assay kit (Life technology, Carlsbad, CA, US) while the size of PCR
products was verified by DNA analysis ScreenTape Assay on Tape Station 2200 (Agilent
Technologies, Santa Clara, CA, US). After quantification, PCR final products were pooled in
equimolar concentration and diluted to 4nM and denatured by NaOH. After combining the
amplicon library and PhiX control, the samples were loaded onto the 600-cycle MiSeq Reagent
kit v3 cartridge and sequenced on an Illumina MiSeq platform (Illumina Inc, San Diego, CA,
US).
3.2.6 Informatic and statistical analysis
Quantitative insights into microbial ecology (QIIME) software pipeline v1.9.1 was used to
analyze the raw data files obtained from Illumina Miseq [149].
Since Miseq platform sequenced multiple samples via single sequencing run, QIIME first
identified each individual samples through DNA barcode after inputting the raw data. Then
QIIME removed sequence reads which have low quality to improve diversity estimates.
Operational Taxonomic Units (OTUs) were clustered into represent groups and assigned to
taxonomy using UCLUST. PyNAST was used in QIIME to align the sequence to constructed
OTU table and phylogenetic tree basing on the public reference database. Alpha-diversity and
rarefaction (number of taxa detected) was calculated and generated basing on the phylogenetic
tree and OTU table. Beta-diversity and rarefaction (relative distribution of taxa in a community)
was calculated and produced UniFrac distance between samples for bacterial 16S rRNA reads
(evenly sampled at 600 reads per sample). UniFrac metric has two variants, weighted and
unweighted. The weighted Unifrac metric consider the number of the OTUs and the relative
abundance of each taxa while unweighted Unifrac metric only takes account of the number of the
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OTUs [150]. The distance matrix were visualized with principal coordinate analysis (PCoA)
which generated a plot with orthogonal axes explaining the maxium difference in the data [151].
The differences in the alpha-diversity were compared using a nonparametric two sample t-test
with 999 Monete Carlo permutations. Results are presented as mean ± SD. The difference of the
beta-diversity were test using ANOSIM with 999 permutations between every two groups.
The functional capacity of the gut microbiota were predicted using PICRUSt software. 16S
rRNA sequences for taxa were input into PICRUSt to aligned KEGG gene orthologs basing on
the Greengenes database [152]. STAMP software were used to calculated the difference among
each group [153]. For all analyses, values of P <0.05 were considered statistically significant.

3.3 Result
3.3.1 Disease activity index, colon length, and spleen enlargement
At day 32, mice in DSS-cranberry group had significantly low DAI scores compared to
the mice in DSS group (p<0.05) (Table 3.2). The colon length in DSS group was significantly
shorter than the colon length in DSS-cranberry group and control group (p<0.05) (Table 3.2).
The spleen weight increased significantly in DSS group compared to the control group while
cranberry diet reverse the weight augment (p<0.05) (Table 3.2).
3.3.2 Histological observation
The colonic specimens obtained from the DSS group showed serious erosive lesions with
inflammatory cell infiltration and crypt shortening. However, in the DSS-cranberry group, the
colonic specimens only had no erosion with just mild inflammatory cell infiltration. In both
control group and control-cranberry group, no aberrant tissue was observed (Fig 3.2).
Histological scores were given to each samples and the DSS group was significant higher than
the DSS-cranberry groups (Table 3.2).
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Table 3.2 Disease activity index (DAI), spleen weight colon length and histological score of
each group
Groups

DAI

Colon length
(cm)

Histological
score

Spleen weight
(mg)

DSS- Cranberry-

0c

87.39 ± 3.85 a

0c

125.35 ± 7.15 b

DSS- Cranberry+

0c

94.19 ± 5.10 a

0c

100.62 ± 4.21 b

DSS+ Cranberry-

3.62 ± 0.42 a

68.98 ± 2.01b

7.11 ± 0.30a

159.25 ± 18.97 a

DSS+ Cranberry+

1.56 ± 0.25 b

80.34 ± 7.42 a

4.55 ± 0.21b

126.29 ± 8.91 b

(A)

(B)

(C)

(D)

Figure 3.2 Histological characterization of the colon mucosa. Hematoxylin and eosin were used
to stain the colon mucosa sample. (A) Control group (B) Control-cranberry group (C) DSS group
(D) DSS-cranberry group
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Figure 3.3A showed the concentration of pro-inflammatory cytokines (IL-1β, IL-10 and
TNF-α) in the colonic mucosa. Compared to the control group mice, the pro-inflammatory
cytokines over expressed in both DSS group mice and DSS-cranberry group mice. However, the
expression of pro-inflammatory cytokines in the DSS-cranberry group mice were significantly
lower than the cytokines level in the DSS group mice. The expression of IL-1β increased 80% in
the DSS group while cranberry diet significantly reduced by 40% (p<0.05). Besides, the
concentration of IL-6 elevated 95% in DSS group but the increasing rate was 65% in DSScranberry group, which significantly suppressed the 33% of the expression (p<0.05). The
expression of TNF- α was enhanced by the DSS treatment by 86% while the cranberry diet
significantly alleviated the expression by 37% (p<0.05).
The expression of cytokines in serum were different from the expression of them in
colonic mucosa (Fig 3.3B). Even though there was slight reduction of the expression of TNF- α
in serum in DSS-cranberry group mice, there was no significant difference between DSScranberry group and DSS group. Besides, the expression of IL-1β in the serum of all three groups
was not high enough to identify by the Elisa kit. However, the concentration of IL-6 in serum
had the similar trend as that in colonic mucosa. The DSS treatment augmented the expression of
IL-6 by 78% while the cranberry diet reduced the augment by 50%. The anti-inflammatory
cytokine IL-10 was significantly increased in both groups receiving DSS treatment. However,
the cranberry diet enhanced the expression by 40% compared to DSS group.
The expression of IL-2, IL-12, CXCL-1and IFN-γ were measured in both colonic mucosa
and serum, which were either no difference or no identified by the kit.
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(A)

(B)

Figure 3.3 Effects of Cranberry treatment on protein levels of IL-1β, IL-6, and TNF-α in the
colonic mucosa of mice (A) and serum (B). Data are shown as the mean ± SD of three
independent experiments. Different letters (a, b, c) indicates statistically significant differences
between groups (p < 0.05, n = 3).
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3.3.4 Impact of cranberry on the composition of gut microbiota in mice
The result of high throughput sequencing were summarized in Table 3.3. In total, eight
prokaryotic phyla were detected in the mice fecal pellet by QIIME. Firmicutes, Bacteroidetes,
Actinobacteria, Verrucomicrobia and Actinobacteria were five major phyla in all the four groups
of mice (Fig. 3.4A), which was similar to other mice gut microbiota research [154]. Liner
discriminant analysis (LDA) was applied to calculate the significant difference of relative
abundance of phyla between different groups. LDA score of each phylum which were greater
than 3.0 between every two groups indicated that the relative abundance of certain phylum in the
group was significant higher than that of the other group (Fig 3.4B). Compared to control group
and control-cranberry group, Verrucomicrobia, TM7 and Proteobacteria were more abundant in
DSS group while Firmicutes and Actinobacteria were less abundant. Besides, the relative
abundance of Verrucoicrobia and TM7 were also higher in DSS-cranberry group than the other
two control groups. DSS group had the more amount of Verrucomicrobia and Proteobacteria
and less amount of Actinobacteria than DSS-cranberry group. However, no difference was found
between two control groups. The difference of these four groups indicated that cranberry
treatment can reverse the alteration of the composition of gut microbiota in DSS group.
In the fourteen classes, Bacteroidia accounted for more than 40% in the four groups:
control group 44.79%, DSS group 40.08%, control_cranberry group. 47.27% and DSS-cranberry
group: 39.81%. The second dominant class were different among four groups. 28.86% and
20.32% of Verrucomicrobiae was identified in DSS group and DSS-cranberry group,
respectively. However, 24.85% of Bacilli was founded in control group. In control-cranberry
group, 24.05% of the bacterial class was Clostridia. Thirty-three families were identified in four
groups of mice fecal pellet, among which, Verrucomicrobiaceae (28.86%) dominated in DSS
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group while family S24-7 in Bacteroidales order was must abundant in control group ( 32.64%),
control-cranberry group (31.82%) and DSS-cranberry group (27.03%).
Moreover, 95 genera which belong to the eight phyla were detected in mice fecal pellet
(Fig. 3.5). Among all the prokaryotic genera, Bifidobacterium, Bacteroides, Lactobacillus,
Akkermansia, Sutterella and two unknown genera in family S24-7 and in order Clostridiales
were the dominating kinds which account for about more than 50% of total bacterial cells. The
relative abundance of each genera was used to calculate the difference between each group.
Compared to control group, the relative abundance of 16 genera in DSS group had shifted
significantly while the relative abundance of 11 genera in DSS-cranberry group had changed
significantly. In control-cranberry group, there were 16 genera whose relative abundance were
significantly different from that in DSS-cranberry group while the relative abundance of 13
genera were different from that in DSS group. Although no difference was detected in the phyla
level between control group and control-cranberry group, 5 genera which had shifted the relative
abundance was founded. Compared to the DSS group, the relative abundance of 15 genera had
changed in DSS-cranberry group, in consistent with the difference in phyla level between these
two groups.

Table 3.3 Summary of high throughput sequencing result
Number of
observations
637

Total count

Minimum
count

Maximum
count

Mean

2754829

62219

272288

137741
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(A)

100%
Verrucomicrobia
Tenericutes
TM7
Proteobacteria
Firmicutes
Deferribacteres
Bacteroidetes
Actinobacteria
Unassigned;Other

80%
60%
40%
20%
0%
DSS+
Cranberry -

DSSCranberry -

DSSDSS+
Cranberry + Cranberry +

(B)

Figure 3.4

(A) Relative abundance of bacteria phyla in 4 sample groups (B) Difference in

relative abundance of bacteria phyla in gut microbiota between sample groups. The LDA effect
size (>3.0) was applied to identify the biomarkers.
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100%

g__Akkermansia
o__RF39;f__;g__
f__F16;g__
f__Enterobacteriaceae;g__
g__Bilophila
g__Sutterella
g__Clostridium
f__Erysipelotrichaceae;g__
f__[Mogibacteriaceae];g__
g__Ruminococcus
g__Oscillospira
f__Ruminococcaceae;g__
f__Ruminococcaceae;Other
g__rc4-4
g__[Ruminococcus]
g__Roseburia
g__Dorea
g__Coprococcus
f__Lachnospiraceae;g__
f__Lachnospiraceae;Other
g__Dehalobacterium
f__Clostridiaceae;g__
o__Clostridiales;f__;g__
o__Clostridiales;Other;Other
g__Turicibacter
g__Lactobacillus
f__Bacillaceae;g__
g__Mucispirillum
f__S24-7;g__
f__Rikenellaceae;g__
g__Parabacteroides
g__Bacteroides
o__Bacteroidales;Other;Other
g__Adlercreutzia
f__Coriobacteriaceae;g__
g__Bifidobacterium

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

DSS+
Cranberry -

DSSDSSCranberry - Cranberry +

DSS+
Cranberry +

Figure 3.5 Relative abundance of bacteria genera in 4 sample groups

3.3.5 Impact of cranberry on the most abundant bacterial genera
Among all 96 genera, the relative of several most abundant bacterial genera had
significantly shifted among different groups (Fig. 3.6). Akkermansia was the most abundant
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genus in DSS group and DSS-cranberry which accounted for 28.27% and 19.32%, respectively,
of the whole composition. However, less than 1% Akkermansia was identified in both control
group and control-cranberry group. The aberrant dominance of Akkermansia in two DSS groups
indicated that DSS treatment was in favor of the growth of Akkermansia, which may promote the
inflammatory process in return. The cranberry diet significantly (p<0.05) reduced the abundance
of Akkermansia in DSS-cranberry treatment, indicating that cranberry can prevent excessively
proliferation of Akkermansia. In addition to Akkermansia, the number of Sutterella increased
significantly (p<0.05) in DSS group (11.01%) and in DSS-cranberry group (2.59%), compared to
control group (0.01%) and control-cranberry group (0.07%). Bilophila proliferated significantly
(p<0.05) in DSS group (3.03%), which was three time more abundant than Bilophila in other
three groups.
In contrast to the DSS group, Lactobacillus was the most abundant genus in the fecal pellet
of mice in control group (24.50%) and control-cranberry group (19.19%). The relative abudance
of Lactobacillus in DSS group and DSS-cranberry group significantly (p<0.05) dropped down to
0.51% and 14.53%, respectively. Besides, compared to DSS group (1.14%), Bifidobacterium
genus were significantly more abundant in other three groups. The abundance of Bifidobacterium
had 50% increasing in control-cranberry group (9.68%) compared to control group (6.51%) and
DSS-cranberry group (6.42%). The abundance of Ruminococcus had decreased significantly
from 2.72% (control group) to 0.46% and 0.43% in DSS group and DSS-cranberry group.
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(A)

(B)

(C)

(D)

(F)

(E)

Figure 3.6 Relative abundance of genera (A) Akkermansia (B) Bilophila (C) Lactobacillus (D)
Ruminooccus (E) Sutterella (F) Bifidobacterium. Each bar represents the mean ± SD. The bars
with letters (a, b, c, d) are significantly different (p<0.05) from each other as determined by
ANONA.
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3.3.6 Impact of cranberry on the α-diversity and β-diversity of gut microbiota
Basing on the sequencing data, the bacterial α-diversity of the group receiving cranberry
diet and normal water was significantly higher in subjects sampled in other three groups, which
means that the most number of species were identified in control-cranberry group (Fig 3.7).
Although the PD value of DSS group was the lowest, there was no significant differences in
bacterial α-diversity among the control group and DSS-cranberry group. Cranberry can
significantly enrich the bacterial diversity while DSS can prevent the enrichment of microbial
richness by cranberry and has slightly reversing effect on the bacterial diversity in normal mice
group. Although the cranberry diet can increase richness of the gut microbiota in the mice, the
amount of these species did not account for enough portion to affect the total community
structure. Therefore, the weighted UniFrac in cranberry diet group did not show significant
difference from that of control diet group. However, the extended cranberry diet may be
continually in favor of the growth of these species, leading to the shift of the community.
DSS alter the structural composition of the microbial community and cranberry attenuate
the alteration (Fig 3.8). ANOSIM with 999 permutations was used to analyze statistical
significance of 4 sample groups using distance matrices of weighted UniFrac. As expected, DSS
significantly altered the gut microbial community of mice fed with control diet (p< 0.05, R=1.0)
and cranberry diet (p< 0.05, R=0.93). Cranberry diet did not significantly shift the gut microbial
community of mice in two groups receiving normal water (p> 0.05, R=0.175). However,
Cranberry significantly alter the gut microbial community of mice in two groups receiving DSS
water (p< 0.05, R=0.75). The community of gut microbiota in the group with DSS water and
cranberry diet was also significantly different from that of the group with normal water and
control diet (p< 0.05, R=0.73). However, the community of gut microbiota in the group with
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normal water and control diet have more similarity with the cranberry diet and DSS water group
than the community of gut microbiota in group with DSS water and control diet (R=1.0>
R=0.73). This suggesting that the cranberry can alleviate the impact of DSS on the gut
microbiota.
3.3.7 Impact of cranberry diet on the microbial function
Predictive metagenomics functional profile indicated that the metagenomics gene of
different groups expressed in different level (Fig 3.9). The proportion of bacterial genes which
related to cancers, neurodegenerative disease and xenobiotics biodegradation were higher in DSS
group than in control group. Meanwhile, the expression level of genes related to cell growth,
replication and repair, digestive system were lower in DSS group than in control group.
Compared to DSS-cranberry group, the relative abundance of six functional genes in DSS group
were higher including excretory system, immune system, cancers, lipid metabolism,
neurodegenerative disease and signal transduction. However, the DSS-cranberry group mice
expressed more genes related to replication and repair, enzyme families, cell growth and death.
The control-cranberry group mice had 15 different gene expression level from the DSScranberry group mice. In control-cranberry group, the proportion of genes related to cell motility,
digestive system and nucleotide metabolism were higher while the proportion of other genes was
lower such as cancers and infectious diseases. The bacterial genes in associate with cell motility,
nucleotide metabolism and replication and repair were more abundant in the control group mice
than in DSS-cranberry group mice. In contrast, the DSS-cranberry group mice had higher
proportion of 5 kinds of genes, including excretory system, cancers, signal transduction, lipid
metabolism and neurodegenerative diseases. There is no difference detected between control
group mice genes expression and control-cranberry group mice.
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Figure 3.7 Bacterial diversity in 4 different sample groups. Box plots of alpha diversity were
generated with rarefication to 60,000 reads per sample. The nonparametric P values were
calculated using 999 Monte Carlo permutations. *, P value = < 0.05

* *

*

Figure 3.8 β-diversity in gut microbiota between groups. Weighted UniFrac distances PCoA
graph was used to evaluate diversities between samples. *, P value <0.05.
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Figure 3.9 Significant differences in relative abundance of predicted metagenome function
between groups. (A) DSS group and control group. (B) DSS group and DSS-cranberry group.
(C) DSS-cranberry group and control group. (D) DSS-cranberry group and control-cranberry
group. The STAMP was used to detect significant differences function.
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3.4 Discussion
Inflammatory bowel disease (IBD) can caused several severe syndromes of the patients,
including abdominal pain, rectal bleeding and diarrhea. The high incidence rate of IBD in
developed countries has been attributed to the western diet with high fat, high calorie and low
consumption of vegetable and fruits. Current therapy for IBD mainly suppress the immune
response in the colon, resulting in the several side effects such as drug toxic and immune damage
[147]. Therefore, the phytochemicals in plants which have been widely studied for their various
bioactivities such as anti-oxidative and anti-inflammatory effect are thought to be a possible and
safe treatment for IBD. The purpose of this study was to investigate the chemopreventive effect
of cranberry on DSS-induced colitis. The results of this study showed that DSS caused severe
colonic inflammatory syndromes in mice including weight loss, diarrhea and rectal bleeding
(Table 3.2). The shorten colon length and the increasing spleen weight further confirmed the
inflammatory process in DSS treated mice. Besides, DSS induced the damage of colonic mucosa
structure, leading to the crypt lesion and inflammatory cell infiltration (Fig 3.1). However, oral
administration of cranberry in diet significantly reversed the inflammatory process and damage
causing by DSS. The DAI score in DSS-cranberry group was significantly lower than DSS
group, indicating that cranberry diet alleviated the syndromes of colitis. No difference in the
colon length and spleen weight was observed between DSS-cranberry group and control group,
which further supported the anti-inflammatory effect of cranberry on the DSS induced colitis.
Studies showed that the inflammation process in the colon is modulated by the expression
level of proinflammatory cytokines, such as IL-1β, IL-2, IL-6, IL-12 IFN-γ and TNF-α and antiinflammatory cytokines like IL-4 and IL-10 [155]. This study used ELISA kit to measure the
concentration of cytokines in colonic mucosa and serum. The result showed that DSS elevated
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the expression of proinflammatory cytokines in colonic mucosa, including IL-1β, IL-6 and TNFα (Fig 3.2). IL-1β modulate the inflammatory process through multiple ways. IL-1β can
promote the activities of dendritic cells, macrophages and neutrophils and activate T cell and
CD4+TH17 cells [156]. TNF-α play an important role on activation of various inflammatory cells
and modulation of epithelial cell permeability [147]. IL-6 is involved in the inflammatory
process through modulating the proliferation of T cell. Over expression of IL-6 can activate the
anti-apoptotic genes Bcl-xl, leading to the expansion of T-cell, which further cause the chronic
intestinal inflammation [157]. The pathological studies indicated that the excessive number of T
cells as well as the increasing level of tumor necrosis factor in the colonic mucosa induce
Crohn’s disease. High level of these three proinflammatory cytokines induced the severe
inflammatory process in DSS mice group. In contrast, the intake of cranberry diet significantly
suppressed the expression of these three cytokines in colonic mucosa, suggesting that cranberry
can prevent the colonic inflammation through reducing the concentration of proinflammatory
cytokines. Besides, the level cytokines in serum also affect the inflammatory process. The result
of serum cytokines showed that DSS enhanced the expression of IL-6 and TNF-α in serum which
was same in colonic mucosa (Fig 3.2). Cranberry diet significantly lower the IL-6 expression and
increased the concentration of IL-10, which is an anti-inflammatory cytokines. IL-10 can
mediate and suppress the expression of proinflammatory cytokines, resulting in the protective
effect against the inflammation and infections [158]. Yanaba et al. also reported that IL-10 can
regulate the proliferation of B10 cells, which suppressed the intestinal inflammation in a mouse
model [159]. By reducing the expression of proinflammatory cytokines and promoting the
secretion of anti-inflammatory cytokines, cranberry significantly ameliorate the inflammatory
process in DSS-induced colitis mice.
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In addition to the over expression of cytokines, accumulated evidence showed that the
development of IBD is associated with the disrupted equilibrium of gut microbiota [86]. Gut
microbiota play an important part in colonic immune system development, which can modulate
both proinflammatory and anti-inflammatory cytokines through their presence or their activity.
Ivanov et al. indicated that germ free mice lack of TH17 cell and was abundant of
CD4+FOXP3+Treg cells in colon [160]. This study used high throughput sequencing to identify
the microbial community structure of the DSS-induced colitis mice and the mice with cranberry
diet. The Firmicutes/Bacterodietes ratio was significantly lower in DSS group (0.43) than in
control group (0.75), control-cranberry group (0.77) and DSS-cranberry group (0.71) (Fig3.3).
The low ratio of Firmicutes/Bacterodietes was widely founded in IBD patients. The
Firmicutes/Bacterodietes ratio in DSS-cranberry group was similar to control group, suggesting
that the cranberry diet can protect the gut microbiota against the DSS. Moreover, the relative
abundance of Verrucomicrobia phylum significantly increased in DSS group, which was mainly
due to the excessive growth of Akkermansia genus (Fig 3.5). Akkermansia is commonly
distributed in the colon of mammals, which locate within the mucus layer and is capable to
degrade mucin. The aberrant number of Akkermansia in DSS group may due to the lesion of
mucus layer caused by the DSS, which may further leaded to the over production of mucin.
Dharmani et al. reported that the increasing Muc2 and Muc 3 gene expression in DSS treated
animal [161]. The increasing amount of mucin can be the food source of Akkermansia and
promoted their growth. However, one study indicated that the abundance of Akkermansia
decresed in the IBD patients, suggesting the beneficial effect of Akkermansia [162]. Derrien et
al. reported that the colonization of in germ free mice did not induce inflammation [163].
Therefore, the excessive proliferation of Akkermansia may be the result of DSS-induced colitis
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rather than the cause of the inflammation. Bifidobacterium and Lactobacillus are generally
regarded as probiotic, which have been proved to reduce the risk of intestinal inflammation. The
reduction of these two bacterial genera in DSS group indicated that inflammatory process may
inhibit the growth of them. However, the cranberry diet counteracted the reduction and the
presence of probiotic and cranberry may exert the anti-inflammatory effect together. The result
showed that DSS treatment reduced the microbial diversity in the gut while the cranberry diet
significantly amplified the diversity in the control group and alleviate the diversity reduction in
DSS group, which protected the bacterial community in colon (Fig 3.6). Moreover, DSS
significantly shifted the microbial community structure while the cranberry diet reversed the
alteration (Fig 3.7). The result of this study showed that DSS-induced colitis changed the
composition and the function of gut microbiota in mice while cranberry ameliorate the alteration
and protect the diversity of the gut microbiota, which may leading to the anti-inflammatory
effect of cranberry.
These results may promote the beneficial health effect of cranberry and the importance of
gut microbiota, which may improve the consumption of cranberry and probiotic product. In
addition, the bioactivity of poor absorbed nutrients will be re-evaluated for their potential ability
to alter the composition of gut microbiota. These results will suggest that cranberry could be the
potential agent to ameliorate the IBD. The further clinical studies will need to be performed to
investigate the interaction between cranberry and gut microbiota in human.
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CHAPTER 4
ANTI-CANCER EFFECTS OF CRANBERRY IN ASSOCIATION WITH GUT
MICROBIOTA
4.1 Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in the
United States and the fourth leading cause of cancer death worldwide. More than 100,000
patients with CRC was diagnosed annually, which make it a serious health threat to human. CRC
is mainly caused by the environmental factors, including environmental and food-borne
carcinogens, gastrointestinal pathobionts and colonic inflammation [4]. There are two major
types of CRC, including sporadic colorectal carcinoma (SCC) and colitis-asscocaited colorectal
cancer (CAC). Epidemiological studies showed that patients with inflammatory bowel disease
are more likely to develop colorectal cancer than the heath people, which confirmed the relation
between chronic inflammation and cancer. Itzkowitz et al. further reported that colitis-associated
colon cancer share several same primary molecular pathway with sporadic colon cancer,
including DNA mutation and hyper-methylation [65]. Hussain et al. indicated that IBD patients
inclined to have more p53 mutation causing by the oxidative damage in the colonic mucosa,
which stimulated DNA mutation during cancer initiation [68].
More than 500 bacterial species live in the human colon, which play an significant role in
human health and disease. Gut microbiota can offer various functions to the host, including
producing vitamins and hormones, training the immune system and digesting the unused energy
substrates. Therefore, gut microbiota maintain a homeostasis with the intestinal immune system
and the interaction between them can affect the growth of both epithelial cells and bacteria [164].
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Gut microbiota can directly metabolize intestinal mucus and dead epithelial cells, which will
affect the function of the colon. One of the microbial metabolites, short chain fatty acids which
are metabolizing from the indigestible carbohydrates was proved to have the ability to mediate
the inflammatory process in colon. Besides, gut microbiota play an important role on
detoxification of and production of carcinogen and mutagen in colon, leading to the different
impact on cancer progression. An AOM-DSS induced colon cancer animal study showed the
colon cancer can be prevented without gut microbiota, which further confirmed that gut
microbiota could be the possible risk factor of colon cancer [165]. Some pathogen in the gut can
cause infection and induce inflammation through toxins production or invasion, resulting in the
promotion of CRC [166]. The dysbiosis of the community of gut microbiota
Cranberry (Vaccinium macrocarpon) is widely consumed in North America for its flavor
and potential health benefits. Cranberry contains various phytochemicals, proanthocyanins,
flavonal, anthocyanins and triterpenoids, which contributes to its anticancer, anti-adhesion and
anti-inflammatory properties.
4.2 Materials and methods
4.2.1 Animals, diets and experimental design
Male CD-1 mice weighting 50-80 g were provided by Charles River Laboratories
(Wilmington, MA, USA). Animals were kept in groups of five mice per cage in a temperaturecontrolled animal room (23 °C) with relative humidity of 65–70%, fixed lighting (12 h day/night
cycle). Mice were fed with AIN93G diet for 2 weeks for acclimation. With free access to water,
mice were then randomly assigned into three groups as follows: the control group, which was fed
with AIN93G diet; the AOM/DSS group, which was fed with AIN93G diet; the cranberry group,
which received the AIN93G diet supplemented with 1.5% w/w whole cranberry for 20 weeks.
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AOM/DSS group and cranberry group were given one intraperitoneal injection of AOM (12
mg·kg-1 body weight) in saline after acclimation. After 1 week, 1.5% (w/v) DSS (molecular
weight: 36,000–50,000, International Lab, Chicago, IL, USA) in drinking water was administered
to the animals for 4 days, followed by 7 days of pure water, and the cycles was repeated four
times. After 20th weeks, CO2 asphyxiation were used to sacrifice the animal (Fig 4.1).
Tissues were removed from the animal and weighed. The length of colon was measured
then weighted after rinsing with phosphate-buffered saline (pH 7.4). Number and size of tumors
of animals were inspected using dissection microscope and measured by an ocular micrometer.
The sizes of tumors were determined by the following formula: tumor volume (mm3) = L × W2 / 2,
where L is the length and W is the width of the tumor. Then the colons were cut into two pieces
longitudinally. Half of the colon was fixed in 10% buffered formalin for 24 h for further
histopathological and immunohistochemical analysis. The other half of the colon was stored at 80°C for ELISA, RT-PCR analysis. Animal experiment was approved by Institutional Animal
Care and Use Committee of the University of Massachusetts Amherst (#2014-0079).

Note: Black shade represents 1.5% DSS water treatment
Figure 4.1 Animal experimental design
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4.2.2 Histological analysis
Formalin-fixed Colonic sections were stained with hematoxylin-eosin (H&E) after
processing for paraffin-embedding and sectioning. The stained samples were observed under a
light microscope (100×) and evaluated for surface epithelial loss and dysplasia [167].
4.2.3 Enzyme-linked immunosorbent assay (ELISA) and real-time PCR analysis
Colonic mucosa were scraped and homogenized in a phosphate buffer solution containing
0.4 M NaCl, 0.05% Tween-20, 0.5% BSA, 0.1 mM benzethonium, and 1% protease inhibitor
cocktail (Boston Bioproducts, Ashland, MA, USA). The homogenates were centrifuged at
10,000g for 30 min at 0°C. The supernatant was used for quantification of cytokines, i.e.
interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) by ELISA kits
(R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. RealTime qRT-PCR analysis was conducted as previously described. The primer pairs were
synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, USA) with the following
primers: IL-1β F: 5′-ACCTGCTGGTGTGTGACGTT-3′, R: 5′-TCGTTGCTTGGTTCTCCTTG3′; IL-6 F: 5′-GAGGATACCACTCCCAACAGACC-3′, R: 5′AAGTGCATCATCGTTGTTCATACA-3′A; TNF-α F: 5′-AGCACAGAAAGCATGATCCG-3′,
R: 5′-CTGATGAGAGGGAGGCCATT-3′; β-actin F: 5′-AAGAGAGGCATCCTCACCCT-3′,
R: 5′-TACATGGCTGGGGTGTTGAA-3′. The copy number of each transcript was calculated
with respect to the β-actin copy number, using the 2−ΔΔCt method [168].
4.2.4 Immunoblotting
Total colonic mucosa was scraped and then lysed in 1 ml of ice-cold lysis buffer with
cocktails of protease inhibitor (1:100), phosphotase inhibitor 1 (1:100), and phosphotase
inhibitor 2 (1:100). Then the smaples were homogenized on ice for 15 s using ultra-sonicator
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probe and centrifuged at 10,000 rpm for 10 minutes at 4 °C. Supernatant were collected and
quantified to determine the protein concentration by BCA protein assay kit. 50-100 µg of total
proteins were loading on SDS-PAGE and transferred on nitrocellulose membrane. The
membrane was further immerged on the target antibodies followed the manufacture’s
recommendation and visualized by Odyssey CLx infrared imaging system (LI-COR Biosciences,
Lincoln, NE, USA). Antibody for p21, p27, cyclin D, CDK 4, p-Rb, cleaved caspase-3, cleaved
PARP, p53, VEGF, MMP-2 and MMP-9 were purchased from Cell Signaling Technology
(Beverly, MA, USA). Anti-β actin antibody was from Sigma-Aldrich (St. Louis, MO, USA).
4.2.5 Isolation of DNA
Fecal pellets were collected from the mice colon to assess gut microbiota. Bacterial DNA
was isolated from feces by using PowerFecal DNA isolation kit (MoBio Laboratories, Inc.,
Carlsbad, CA) according to the manufacturer’s protocols.
4.2.6 16S rRNA Analysis
The concentration of the DNA samples was measured by NanoDrop Spectrophotometer
(Thermo Scientific, Waltham, MA, US). PCR was performed to amplify the 16s rRNA gene
marker using region of interest-specific primers with overhang adapters attached, which of
sequences are: 16S Amplicon PCR Forward Primer =
5'TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG) and
(16S Amplicon PCR Reverse Primer =
5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC)
[148]. 2x KAPA HiFi Hotstart ReadyMix (KAPA Biosystem, Wilmington, MA, US) was used as
PCR reagent. Then PCR product was cleaned and purified by using AMPure XP beads
(Beckman Coulter, Danvers MA, US). A second PCR was performed to attach dual indices and
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Illumina sequencing adapters using the Nextera XT Index Kit (Illumina, San Diego, CA, US)
followed by AMPure XP bead purification. The quantity of PCR products was determined by
using Qubit dsDNA BR Assay kit (Life technology, Carlsbad, CA, US) while the size of PCR
products was verified by DNA analysis ScreenTape Assay on Tape Station 2200 (Agilent
Technologies, Santa Clara, CA, US). After quantification, PCR final products were pooled in
equimolar concentration and diluted to 4nM and denatured by NaOH. After combining the
amplicon library and PhiX control, the samples were loaded onto the 600-cycle MiSeq Reagent
kit v3 cartridge and sequenced on an Illumina MiSeq platform (Illumina Inc, San Diego, CA,
US).
4.2.7 Informatic and Statistical analysis
Quantitative insights into microbial ecology (QIIME) software pipeline v1.9.1 was used to
analyze the raw data files obtained from Illumina Miseq [149].
Since Miseq platform sequenced multiple samples via single sequencing run, QIIME first
identified each individual samples through DNA barcode after inputting the raw data. Then
QIIME removed sequence reads which have low quality to improve diversity estimates.
Operational Taxonomic Units (OTUs) were clustered into represent groups and assigned to
taxonomy using UCLUST. PyNAST was used in QIIME to align the sequence to constructed
OTU table and phylogenetic tree basing on the public reference database. Alpha-diversity and
rarefaction (number of taxa detected) was calculated and generated basing on the phylogenetic
tree and OTU table. Beta-diversity and rarefaction (relative distribution of taxa in a community)
was calculated and produced UniFrac distance between samples for bacterial 16S rRNA reads
(evenly sampled at 600 reads per sample). UniFrac metric has two variants, weighted and
unweighted. The weighted Unifrac metric consider the number of the OTUs and the relative
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abundance of each taxa while unweighted Unifrac metric only takes account of the number of the
OTUs [150]. The distance matrix were visualized with principal coordinate analysis (PCoA)
which generated a plot with orthogonal axes explaining the maxium difference in the data [151].
The differences in the alpha-diversity were compared using a nonparametric two sample t-test
with 999 Monete Carlo permutations. Results are presented as mean ± SD. The difference of the
beta-diversity were test using ANOSIM with 999 permutations between every two groups.
The functional capacity of the gut microbiota were predicted using PICRUSt software. 16S
rRNA sequences for taxa were input into PICRUSt to align to to Kyoto Encyclopedia of Genes
and Genomes (KEGG) gene orthologs basing on the Greengenes database [152]. STAMP
software were used to calculate the difference among each group [153]. For all analyses, values
of P <0.05 were considered statistically significant.
4.3 Results and discussion
4.3.1 Cranberry reduced the incidence and multiplicity of colonic tumors in AOM/DSS
Model
Injection of a colon carcinogen AOM in combination with cyclic administration of DSS
in drinking water resulted in the development of colitis, colorectal dysplasia, and cancer. Body
weight was monitored twice a week as an indicator of potential toxicity of cranberry, and no
difference was found between cranberry-treated group and the control during the whole
experimental period (final body weights were shown in the Table 4.1). There was no difference
in the weight of liver and spleen between the two groups (Table 4.1), and no apparent behavioral
or appearance difference was observed either, suggesting no noticeable toxic effects caused by
dietary feeding of cranberry to the mice. Colon weight/length ratio is correlated with the severity
of colitis and therefore is an indicator of levels of inflammation in the colon. As shown in Table
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4.1, compared to the control group, dietary treatment with cranberry significant prevented the
shortening of colon length and reduced the elevated colon weight/length ratio caused by
AOM/DSS. The AOM/DSS treatment resulted in 100% incidence of colon tumors and 4.97 ±
1.01 colonic tumors per mouse. Dietary administration of cranberry significantly decreased the
tumor incidence by 50% and tumor multiplicity by 65%. These results demonstrated that
cranberry effectively suppressed AOM/DSS-induced colon carcinogenesis in mice.
Table 4.1 Final body weight, relative organ weights, and colon assessment of mice
Group

AOM/DSS-

AOM/DSS+

AOM/DSS+
Cranberry+

Treatment

None

AOM/DSS

AOM/DSS/1.5%
Whole cranberry

Body weight (g)

50.96± 1.47

48.33 ± 1.22

49.45 ± 1.23

Liver weight (mg)

2348.85 ± 78.36

2263.99 ± 94.74

2199.85 ± 55.20

Spleen weight (mg)

238.18± 35.58

230.67 ± 30.15

194.58 ± 16.84

Colon length (mm)

96.62 ± 2.42 a

87.80 ± 2.90 b

92.69 ± 2.99a

Colon weight (mm)

353.96 ± 35.47

357.84 ± 46.07

367.53 ± 56.22

Colon W/L ratio
3.69± 0.29 a
4.00 ± 0.40 b
4.86± 0.84 c
(mg/mm)
Tumor incidence
80% b
53% c
0a
Tumor multiplicity
0a
5.91 ± 1.01 b
2.77 ± 0.88 c
Data are shown as the mean ± SD. *p < 0.05 (n = 10) versus the control group.
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(A)

(B)

(C)

Figure 4.2 Histological characterization of the colon mucosa. Hematoxylin and eosin were
used to stain the colon mucosa sample. (A) Control group (B) AOM/DSS-cranberry group (C)
AOM/DSS group
4.3.2 Histological observation
The colonic specimens obtained from the AOM/DSS group showed developed invasive
mucinous adenocarcinoma with inflammatory cell infiltration. However, in the AOM/DSS
group, the colonic specimens had no erosion with just mild inflammatory cell infiltration. In
control group, no aberrant tissue was observed (Fig 4.2).
4.3.3 Cranberry decreased the levels of pro-inflammatory cytokines in the colon of
AOM/DSS Model
Accumulating studies have demonstrated that improper up-regulation of proinflammatory cytokines such as interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis
factor-α (TNF-α) can accelerate the process of colon carcinogenesis. Using ELISA, we
determined the effects of cranberry on the AOM/DSS-induced production of pro-inflammatory
cytokines in colonic mucosa. As shown in Figure 4.3A, cranberry treatment resulted in
significant decreases in the levels of IL-1β, IL-6 and TNF-α by 83%, 70% and 45%, respectively,
compared to those of the control group. Next, we determined the effects of cranberry on the
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mRNA expression levels of pro-inflammatory cytokines by Real-Time PCR analysis. As shown
in Figure 4.2B, the mRNA expression levels of IL-1β, IL-6, and TNF-α were significantly
reduced by cranberry treatment by 91%, 89%, and 95%, respectively, in comparison with those
found in the AOM/DSS treatment mice. Together, our results showed that oral administration of
cranberry inhibited the colon carcinogenesis at least partially by reducing cell proliferation,
inducing apoptosis, and suppressing the expression levels of pro-inflammatory cytokines in the
colon of AOM/DSS-treated mice.
4.3.4 Cranberry mediated the expression level of key proteins related with cell cycle
progression, apoptosis, angiogenesis and metastasis in AOM/DSS-treated mice
In order to understand the molecular mechanism of the anti-cancer effect of cranberry on
AOM/DSS-treated mice, this study analyzed the expression of signaling proteins involved in the
apoptosis (p53, cleaved caspase-3 and cleaved PARP) in colonic mucosa. Figure 4.4A showed
that cranberry diet increased the expression of all three proteins, indicating that cranberry can
regulate the apoptosis. Besides, the expression of cell cycle signal protein (p21, CDK4, cyclin D
and p-Rb) were also measured. Figure 4.4B showed that the expression of p21 and p27 were 3
fold and 4-fold higher while the expression of cyclin D and CDK4 were lower in cranberry
group, compared to the AOM/DSS group, suggesting that cranberry could induce cell cycle
arrest in G1 phase. Moreover, the expression of signal proteins involved in the angiogenesis and
metastasis was significantly lower in the cranberry group than AOM/DSS group. The expression
of VEGF was 2-fold lower and MMP-2 and MMP-9 were 4-fold lower in the cranberry group
(Fig 4.4C). The alteration of the expression of signal protein indicated that cranberry prevented
the cancer progression through multiple pathway.
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(A)

(B)

Figure 4.3. Effects of Cranberry treatment on protein levels (A) and mRNA levels (B) of IL-1β,
IL-6, and TNF-α in the colonic mucosa of AOM/DSS-treated mice. Data are shown as the mean
± SD of three independent experiments. The amount of IL-1β, IL-6, TNF-α mRNA expression
was normalized to that of β-actin. * indicates statistically significant differences from the control
group (p < 0.01, n = 3).

66

Figure 4.4. Effects of cranberry on cancer related signaling proteins in the colonic mucosa of
AOM-treated mice. The numbers underneath of the blots represent band intensity (normalized to
β-actin, means of three independent experiments) measured by Image J software. The SDs (all
within ±15% of the means) were not shown. β-Actin was served as an equal loading control. *
indicates statistical significance in comparison with the control (p < 0.05, n=3).
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4.3.5 Impact of cranberry on the composition of gut microbiota in AOM/DSS-treated mice
Five mice were housed per cage and fecal pellets from each cage were collected and
pooled after sacrificing. In order to characterize phylogenetic diversity, the 16S rRNA gene
V3/V4 fragment sequencing yielded 336,876 quality reads following filtering. This provided a
mean sample depth of 37,430 sequencing reads per bacterial community.
At the phylum level, Actinobacteria, Bacteroidetes, Deferribacteres, Firmicutes,
Proteobacteria, Verrucomicrobia together constituted over 99% of OTUs identified in the total
samples analyzed (Fig. 4.5). Compared to the control group, the relative abundances of
Firmicutes significantly decreased while the relative abundance Proteobacteria significantly
increased by 40% in AOM/DSS group. However, there was no significant alteration in
AOM/DSS-cranberry group.
4.3.6 Impact of cranberry on the most abundant bacterial genera
At the genus level, AOM/DSS treatment and cranberry treatment exert different impact on
the bacteria (Fig. 4.9). Three bacterial genus which are widely regarded as disease related
increased after AOM/DSS treatment and cranberry treatment inhibited the growth of them.
Compared to the control group, the relative abundance of Clostridium, Escherichia and
Staphylococcus increased by 50%, 16%, 63%, respectively in AOM/DSS group. In contrast, no
difference was founded between cranberry group and control group in terms of these genera. In
addition, AOM/DSS treatment suppressed the growth of Akkermansia, Bifidobacterium and
Lactobacillus while cranberry treatment attenuated the alteration. Akkermansia is a mucin
degrading bacterium which proved to have ability to control inflammation. Bifidobacterium and
lactobacillus are considered as important probiotic which may exert a range of beneficial health
effects, such as the inhibition of harmful bacteria and modulation of immune responses.
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Figure 4.5 Relative abundance of bacterial phylum in response to AOM/DSS treatment and
cranberry
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Figure 4.6 Statistical comparisons of bacteria at genus level. Data are shown as the mean ± SD.
*p < 0.05 (n = 3).
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4.3.7 Impact of cranberry on the α-diversity and β-diversity of gut microbiota
According to the high throughput sequencing data, the microbial α-diversity of cranberry
groups was slightly higher than the other two groups, suggesting that the cranberry contributed to
the microbial species diversity (Fig 4.7). However, there was no significant difference on the αdiversity among these three groups, which means that AOM/DSS treatment did not alter the
microbial richness in the mice.
Figure 4.8 showed that AOM/DSS treatment had shifted the microbial community while
cranberry alleviated the effect of AOM/DSS on gut microbiota. ANOSIM with 999 permutations
was used to analyze statistical significance among three groups using distance matrices of
weighted UniFrac Compared to the control group. AOM/DSS treatment significantly altered the
bacterial community of gut microbiota in mice which had been consuming normal diet (p<0.05,
R=1.0). Bisides, the microbial community in cranberry group was also different from that in
control group (p<0.05, R=0.71) and in AOM/DSS group (p<0.05, R=0.95). However, the
microbial community in cranberry group mice have more similarity with the bacterial
community in the control group mice than in the DSS group (R=1.0>R=0.73).
β-diversity of gut microbiota is a value which evaluate the number of observed species in
the sequencing samples and the quantity of each species while α-diversity only take the number
of species into account. Therefore, the result of this study suggested that AOM/DSS treatment
can affect the growth of gut microbiota while the cranberry can reverse or attenuate the effect
and protect the microbial community, leading to the protective effect on the host.

71

Figure 4.7 Bacterial diversity in 3 different sample groups. Box plots of alpha diversity were
generated with rarefication to 30,000 reads per sample. The nonparametric P values were
calculated using 999 Monte Carlo permutations.

Figure 4.8 β-diversity in gut microbiota between groups. Weighted UniFrac distances PCoA
graph was used to evaluate diversities between samples. *, P value <0.05.
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4.3.8 Cranberry influenced predicted metagenomics function of gut microbiota of
AOM/DSS Model
The metagenomics potential in the treatment groups were inferred by Phylogenetic
Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) based on 16s
rRNA phylogenetic data. A total of 336,876 observations were predicted across Kyoto
Encyclopedia of Genes and Genomes (KEGG) orthology groups (KO). The resultant data were
categorized into 182 functional pathways encompassing the 9 samples. (Fig. 4.9).
In control group, the expression of 24 functional genes were significantly different from the
AOM/DSS group. The proportion of genes in associate with cancer, which has 24 kinds of
genetic function related to different kinds of cancer like colorectal cancer was significantly more
abundant in of AOM/DSS group. Besides, compared to the AOM/DSS group, bacterial genes
which related to the energy metabolism, metabolism of cofactors and vitamins and glycan
biosynthesis were significantly higher in both control group and cranberry group, indicating that
the microbial activities in these two groups are more active. In contrast, disease related genes
such as immune system disease and neurodegenerative diseases were more abundant in
AOM/DSS group, suggesting the potential over growth of pathogen.
In AOM/DSS group, genes related to cell growth and death and replication and repair had
lower relative proportion while signal transduction genes had higher proportion, compared to
other two groups, which means that the overall growth of bacterial cells may be slightly inhibited
by AOM/DSS treatment while cranberry counteracted this detrimental alteration. The difference
in predicted genome function further confirmed that the community of gut microbiota is
associated with their function, which may affect their interaction with the host and the
immunological balance.
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Figure 4.9 Significant differences in relative abundance of predicted metagenome function
between groups. (A) AOM/DSS group and control group. (B) AOM/DSS group and AOM/DSScranberry group.
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4.3.9 Microbiota-host networks in AOM/DSS model
Correlation networks was built among bacterial relative abundances from 16s rRNA gene
amplicon sequencing, qPCR data from pro-inflammatory cytokines and tumor formation data of
mice (Fig. 4.10). Data was log-normalized and the Pearson correlation coefficients r>0.6 or r<0.6 were used to construct and visualized the correlation networks in R software environment.
IL-6, IL-1β and TNF-α expression levels correlated with tumor formation and members of this
cluster correlated positively with OTU 1(Escherichia), OTU 2 (Clostridium) and OTU 3
(Staphylococcus) while negatively with OTU 4 (Bifidobacterium), OTU 5 (Lactobacillus), OTU
6 (Akkemansia).

OTU 1
OTU 2
OTU 6

IL-1β

OTU 4

IL-6

OTU 5
OTU 3

Tumor
Formation
TNF-α
Figure 4.10 Correlation networks of 16s rRNA gene amplicon defined OTUs and host
parameters
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4.4 Discussion
Since cranberry and its phytochemicals were proved to have the anti-inflammatory and
antioxidant effect, this study evaluated the anti-cancer properties of cranberry against colon
cancer. In vitro study had been showed that phytochemicals extracted from cranberry such as
ursolic acid, quercetin and proanthoanidins significantly inhibited the proliferation of HepG2
human liver cancer cells and MCF-7 breast cancer cells [110]. The result of this study were in
consistence with the in vitro studies showing that oral administration of whole cranberry in diet
protected the CD-1 mice from developing colitis-associated colon carcinogenesis after
AOM/DSS-treatment. The result demonstrated cranberry played an important role in modulating
the expression of signal proteins of the cell cycle, cell apoptosis, angiogenesis and metastasis in
colonic mucosa, leading to its anti-cancer properties. Furthermore, this study proved that
cranberry mediated the expression of pro-inflammatory cytokines, resulting in the prevention of
cancer progression.
Moreover, as expected, AOM/DSS-treatment significantly shifted the microbial
community in mice which may lead to the dysfunction of immune system and promote the
development of adenoma. However, cranberry exerted protective effect on gut microbiota
against the stimulation and inflammation. This effect was associated with alleviation of
inflammation and the alteration of the structure of gut microbiota community. Our study further
suggests that the ability of whole cranberry administration to inhibit the relative abundance of
disease related bacteria while protect the health related bacteria is playing a important role in this
protective effect. Moreover, the pooling of the mice feces samples bring the limitation of this
study, but allowed us to focus on the alteration happening within the dominant phylum level due
to the different treatment. This study provided a solid scientific basis for using whole cranberry
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as a chemopreventive agent for colon cancer in human. Even though studies widely investigated
the beneficial activities of pure phytochemicals in cranberry, the potent anticancer property of
cranberry may be the additive and synergistic effects of all the phytochemicals in cranberry.
Further study can focus on the identification and evaluation of effective phytochemicals in
cranberry.
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